None listed
Conditions
Interventions
Drug : The subjects are to be randomly assigned to either the evogliptin group or the glimepride group.
-Evogliptin group : Evogliptin 5 mg tablets to be administered orally, once a day for 104 weeks
s blood sugar control.
Sponsors
Kyungpook National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. T2DM patients, diagnosed at least 3 months ago 2. HbA1c 6.5~10% 3. Age 30-90 years 4. Drug naïve or with previous metformin +/- insulin users 5. 10~75% of coronary stenosis in the initial coronary CT angiography.
Exclusion criteria
Exclusion criteria: 1. T1DM, secondary diabetes 2. Patients with advanced CKD (eGFR <50) 3. Patients with severe allergic reaction to contrast media 4. Patients with prior CABG/PCI 5. Severe liver dysfunction (OT/PT, above 120 IU/l) 6. Previous history of DPP4-inhibitor administration more than 6 months 7. Presence of severe infectious disease, before or after surgery or severe trauma 8. Moderate to severe heart failure (above NYHA stage III) 9. Pregnant, lactating, possibly pregnant women 10. Past medical history of hypersensitivity to investigational drugs 11. Clopidogrel, cilostazol users (aspirin or statin users are allowed to be enrolled)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in atherosclerotic plaque analyzed by coronary CT angiography | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of intima-medial thickness;The change of ankle-brachial index;The changes of plaque volume(Non-calcified, calcified, fibrous, fibrous fatty, and low attenuation plaque) using CCTA;The change of body composition | — |
Countries
Korea, Republic of
Contacts
Public ContactInkyu Lee
Kyungpook National University Hospital
Outcome results
None listed